The molecular framework of pediatric-type diffuse gliomas: shifting toward the revision of the WHO classification of tumors of the central nervous system-Reference-Cited by-同舟云学术

The molecular framework of pediatric-type diffuse gliomas: shifting toward the revision of the WHO classification of tumors of the central nervous system

Published:2021-01 Issue:1 Volume:38 Page:1-3
ISSN:1433-7398
Container-title:Brain Tumor Pathology
language:en
Short-container-title:Brain Tumor Pathol

Author:

Komori Takashi

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Neurology (clinical),Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s10014-020-00392-w.pdf

Reference20 articles.

1. Collins VP, Jones DTW, Giannini C (2015) Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol 129:775–788

2. Ellison DW, Hawkins C, Jones DTW et al (2019) cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF(V600E) mutation. Acta Neuropathol 137:683–687

3. Jain SU, Khazaei S, Marchione DM et al (2020) Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression. Proc Natl Acad Sci USA 117:27354–27364

4. Jones DTW, Bandopadhayay P, Jabado N (2019) The power of human cancer genetics as revealed by low-grade gliomas. Annu Rev Genet 53:483–503

5. Khuong-Quang DA, Buczkowicz P, Rakopoulos P et al (2012) K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124:439–447

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glioneuronal and neuronal tumors: A perspective;Pathology International;2024-09-06

2. Neuroradiological, genetic and clinical characteristics of histone H3 K27-mutant diffuse midline gliomas in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort;Acta Neuropathologica Communications;2024-07-27

3. Ex Vivo Modeling of the Tumor Microenvironment to Develop Therapeutic Strategies for Gliomas;Advanced Therapeutics;2024-06-16

4. Glioma: bridging the tumor microenvironment, patient immune profiles and novel personalized immunotherapy;Frontiers in Immunology;2024-01-11

5. Different states of stemness of glioblastoma stem cells sustain glioblastoma subtypes indicating novel clinical biomarkers and high-efficacy customized therapies;Journal of Experimental & Clinical Cancer Research;2023-09-21